Oncogenic role of plakophilin-1 in non-small cell lung cancer

  1. MARTÍN PADRÓN, JOEL
Dirigée par:
  1. Pedro Pablo Medina Vico Directeur
  2. María Esther Farez Vidal Directrice

Université de défendre: Universidad de Granada

Fecha de defensa: 30 janvier 2020

Jury:
  1. Antonio Sánchez Pozo President
  2. Jesús Manuel Torres de Pinedo Secrétaire
  3. Valentina Iadevaia Rapporteur
  4. Juan Carlos Rodriguez Manzaneque Escribano Rapporteur
  5. María Teresa Valero Griñán Rapporteur
Département:
  1. BIOQUÍMICA Y BIOLOGÍA MOLECULAR I

Type: Thèses

Résumé

Plakophilin 1 (PKP1) is a member of the arm-repeat (armadillo) and plakophilin gene families and it is an essential component of the desmosomes. Although desmosomes have generally been associated with tumor suppressor functions, we have consistently observed that PKP1 is among the top overexpressed proteins in squamous cell lung cancer. To explore this paradox, we developed in vivo and in vitro functional models of PKP1 gain/loss in squamous cell lung cancer. CRISPR-Cas9 PKP1 knock-out severely impaired cell proliferation, but it increased cell dissemination. In addition, PKP1 overexpression increased cell proliferation, cell survival and in vivo xenograft engraftment. We further investigated the molecular mechanism of the mainly oncogenic function of PKP1 by combining transcriptomics, proteomics and protein-nucleic acid interaction assays. Interestingly, we found that PKP1 enhances MYC translation in collaboration with the translation initiation complex by binding to the 5’-UTR of MYC mRNA. We propose PKP1 as an oncogene in SqCLC and a novel post-transcriptional regulator of MYC. PKP1 may be a valuable diagnostic biomarker and potential therapeutic target for SqCLC. Importantly, PKP1 inhibition may indirectly target MYC, a primary anti-cancer target.